Sign Up Now to Download a Free Research Report on
Sign-Up to Get the Equity Report on this Company Plus Exclusive Access to Our Winning Newsletter Alerts
Having problems viewing PDF files? OXiGENE, Inc.
OXiGENE shares of the biotech company were sent soaring after reporting the combination of ZYBRESTAT and Avastin has again demonstrated acceptable tolerability in a second interim and final toxicity analysis. OXiGENE posted a gain of nearly 20 percent on over 1 million shares traded Thursday.
Going forward .... (see research report)
Subscribe to News Feeds